B+
Bull case
25%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
ABEO
Abeona TherapeuticsANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
ZEVASKYN is showing early commercial traction through sequential revenue growth, expanding treatment-center access, and upcoming NTAP reimbursement. The $146.8 million cash balance provides near-term flexibility, though runway quality depends on launch execution.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.9.
What can break
ABO-701 remains preclinical with IND and first-in-human timing targeted for the second half of 2027; ophthalmology programs were deprioritized.
Momentum
15
Value
44
Sentiment
93
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.00 · Bull $10.00 · Bear $3.50Analysis 2026-08-18; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-18 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $18.86
Why
Momentum15 · Δ7d -12.8
Value44 · Δ7d -0.0
Sentiment93 · Δ7d +6.9
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +6.9.
Contradictions & invalidation
- • ABO-701 remains preclinical with IND and first-in-human timing targeted for the second half of 2027; ophthalmology programs were deprioritized.
- • Cash burn and ongoing commercialization costs remain important despite $146.8 million in cash, equivalents, and short-term investments as of June 30, 2026.
- • Revenue conversion remains vulnerable to manufacturing yield, lot-release, patient-health, and scheduling issues.
Catalyst clock
2026-08-13
Post-earnings ZEVASKYN launch progress
Lead driver: Sentiment · See AI snapshot
Momentum
15
9% active weight
Current posture
7d trendSoftening
Δ7d
-12.8
Δ21d
-33.9
Value
44
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
93
62% active weight
Current posture
7d trendImproving
Δ7d
+6.9
Δ21d
+6.4
Why this grade
Composite grade A. Momentum 14.5 / Value 44.3 / Sentiment 93.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-18. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$3.50
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$339.67M
Beta
1.17
Shares Out
57.18M
P/E (TTM)
4.7
P/S (TTM)
707.20
P/FCF (TTM) · Derived
-4.05
Rev YoY
+2745.0%
EPS YoY
-120.7%
Gross Margin
+47.2%
Op Margin
+17289.3%
Net Debt
-$166.44M
Current Ratio
6.63
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data